11 Best Short Squeeze Stocks to Buy Now

Page 2 of 10

9. Summit Therapeutics Inc. (NASDAQ:SMMT)

Short Float: 25.63%

Summit Therapeutics Inc. (NASDAQ:SMMT) earns a spot in our list of 11 best short squeeze stocks to buy now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines.

The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in clinical trials for non-small cell lung cancer. The Miami-based company currently holds regulatory collaborations for commercialization across multiple global regions.

On May 30, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced mixed results from the trial of its antibody treatment for lung cancer, Ivonescimab. In a comparison study, the drug had initially performed better than Merck’s Keytruda. But the latest evaluation revealed both promising and less favourable outcomes.

Later, on June 30, 2025, the company entered a new clinical collaboration with Revolution Medicines to evaluate combinations of three RAS(ON) inhibitors with Ivonescimab in RAS mutant tumours. The aim is to assess the safety and efficacy of these combinations across three priority tumour types, including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).

Initial study stands positive with evidence suggesting that Revolution Medicines’ inhibitors in combination with a PD-1 antibody can deliver additive antitumor activity safely in patients with RAS mutant NSCLC. This has created anticipation for further therapeutic benefits with novel PD-1 bispecific inhibitors like Ivonescimab.

With favorable developments triggering sharp upside movements, the company’s short float of 25.63% remains attractive to short-squeeze investors.

Page 2 of 10